Hormonal treatment effectivity in hyperandrogenic syndrome

Czech version

Authors: J. Višňovský ¹; K. Biringer ¹; I. Švecová ¹; Z. Biringerová ²
Authors‘ workplace: Gynekologicko-pôrodnícka klinika JLF UK, Martin, Slovensko, prednosta prof. MUDr. J. Danko, CSc. ¹; Klinika anesteziológie a intenzívnej medicíny JLF UK, Martin, Slovensko, prednosta doc. MUDr. B. Sániová, CSc. ²
Published in: Ceska Gynekol 2010; 75(5): 481-485

Overview

Objective:
To evaluate effectiveness of hormonal treatment of hyperandrogenic syndrome (HAS).

Design:
Prospective randomized study.

Setting:
Department of Gynecology and Obstetrics, Jessenius Faculty of Medicine, Comenius University, Martin, Slovak Republic.

Methods:
We assessed effect of one-year-long hormonal treatment on menstrual cycles (MC), clinical signs of HAS, and ultrasound finding (USG) in 90 patients with HAS. Patients were divided into three groups with 30 females: A – 35 μg ethinylestradiol (EE) with 2.0 mg cyproterone acetate/day; B – 30 μg EE with 2.0 mg dienogest/day; C – 30 μg EE with 3.0 mg drospirenone/day.

Results:
It was achieved a positive effect on MC regularity in every group during the first six months of treatment (p<0.001). Signs of hirsutism, virilization, and USG finding were significantly better in group A.

Conclusion:
The most effective hormonal treatment in our study was the combination of 35 μg EE with 2.0 mg cyproterone acetate/day.

Key words:
hyperandrogenic syndrome, HAS, PCOS, menstrual bleeding, ultrasound.

Sources

1. Azziz, R., Woods, K.S., Reyna, R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab, 2004, 89, p. 2745–2749.

2. Batukan, C., Muderris, I.I. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril, 2006, 85, 2, p. 436-440.

3. Bilgir, O., Kebapcilar, L., Taner, C., et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). Inter Med, 2009, 48, p. 1193-1199.

4. Cibula, D., Hill, M., Vohradníková, O., et al. The role of androgens in determining acne severity in adult women. Br J Dermatol, 2000, 53, p. 78-91.

5. Cibula, D., Živný, J., Stárka, L. Syndrom polycystických ovarií. Aktuální endokrinologie. Praha: Maxdorf, 1999,126 s.

6. Franks, S., Layton, A., Glasier, A. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Human Reproduction, 2008, 23, 2, p. 231–232.

7. Franks, S. Adult polycystic ovary syndrome begins in childhood. Best Pract Clin Endocrin Metab, 2002, 32, 1, p. 71-75.

8. Gandar, R., Spizzo, M., Collin, D. Diagnostic at treatment du syndrome des ovaries polycystigues. J Gynekol Obstet Biol Reprod (Paris), 1999, 28, 6, p. 510-518.

9. Guido, M., Romualdi, D., Giuliani, M., et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab, 2004, 89, 6, p. 2817-2823.

10. Kidson, W. Polycystic ovary syndrome: a new direction in treatment. Human Reprod Update, 1996, 8, p. 231-241.

11. Lobo, RA. Choice of treatment for women with polycystic ovary syndrome. Fertil Steril, 2006, 86, Suppl. 1, p. S22–S23.

12. Mathur, R., Levin, O., Azziz, R. Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. Ther Clin Risk Manag, 2008, 4, 2, p. 487-492.

13. Moore, C., Walter, F., Mellinger, U., et al. Multicentre study on contraceptive safety, cycle control and tolerance of MP 2000 Micropille: an interim report. In: Teichmann, AT., ed. Dienogest: Präklinik und Klinik eines Gestagens. 2nd ed. Berlin: Walter de Gruyter, 1995, S. 203-212.

14. Palep-Singh, M., Mook, K., Barth, J., Balen, A. An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care, 2004, 30, 3, p. 163-165.

15. Palombo-Kinne, E., Schellschmidt, I., Schumacher, U., Gräser, T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception, 2009, 79, 4, p. 282-289.

16. Rabe, T., Kowald, A., Ortmann, J., Rehberger-Schneider, S. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol, 2000, 14, 4, p. 223-230.

17. Raudrant, D., Rabe, T. Progestogens with antiandrogenic properties. Drugs, 2003, 63, 5, p. 463-492.

18. Zimmermann, T., Dietrich, H., Wisser, KH., et al. Efficacy and tolerability of the dienogest-containing oral contraceptive Valette (R); results of a postmarketing surveillance study. Drugs Today, 1999, 35, Suppl C, p. 79-87.